Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)
Lake Street analyst Thomas Flaten maintains a Buy rating for Diamedica Therapeutics with a $14.00 price target. Flaten, who covers the Healthcare sector, has an average return of 18.0% and a 54.15% success rate. Diamedica has a Strong Buy consensus with a $17.00 price target.
In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Diamedica Therapeutics, with a price target of $14.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Flaten covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Insight Molecular Diagnostics, and Evaxion Biotech. According to TipRanks, Flaten has an average return of 18.0% and a 54.15% success rate on recommended stocks.
Diamedica Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
